乳腺癌转移相关机制

摘要/Abstract

摘要：乳腺癌在女性中有着高发病率和死亡率。虽然目前针对乳腺癌有了多种治疗方法，但是乳腺癌的转移仍是一个棘手的医学问题。目前，乳腺癌相关转移机制主要涉及上皮间质转化、细胞外基质的溶解、循环肿瘤细胞或播散性肿瘤细胞、肿瘤血管和肿瘤微环境等。乳腺癌相关转移机制的明确对预测和治疗乳腺癌转移有一定的指导意义。

钟晶敏,曾亮. 乳腺癌转移相关机制[J]. 国际肿瘤学杂志, 2015, 42(2): 141-143.

Zhong Jingmin, Zeng Liang. Metastatic mechanisms of breast cancer[J]. Journal of International Oncology, 2015, 42(2): 141-143.

［1］ Wang B, Li J, Sun M,et al. MiRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features［J］. IUBMB Life, 2014, 66(5): 371-377. ［2］ Lagadec C, Romon R, Tastet C, et al. Ku86 is important for TrkA overexpressioninduced breast cancer cell invasion［J］. Proteomics Clin Appl, 2010, 4(6-7): 580-590. ［3］ Lee HH, Lim CA, Cheong YT, et al. Comparison of protein expression profiles of different stages of lymphnodes metastasis in breast cancer［J］. Int J Biol Sci, 2012, 8(3): 353-362. ［4］ Mathias RA, Simpson RJ. Towards understanding epithelialmesenchymal transition:a proteomics perspective［J］. Biochim Biophys Acta, 2009, 1794(9): 1325-1331. ［5］ Liu J, Chen Y, Shuai S, et al. TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK3β pathway［J］. Tumour Biol, 2014, 35(9): 8969-8977. ［6］ Zeng Q, Zhang P, Wu Z, et al. Quantitative proteomics reveals ERα involvement in CD146induced epithelialmesenchymal transition in breast cancer cells［J］. J Proteomics, 2014, 103: 153-169. ［7］ Foroni C, Broggini M, Generali D, et al. Epithelialmesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact［J］. Cancer Treat Rev, 2012, 38(6): 689697. ［8］ Descotes F, Jézéquel P, Spyratos F, et al. Identification of potential prognostic biomarkers for nodenegative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study［J］. Int J Oncol, 2012, 41(1): 92-104. ［9］ Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using twodimensional differential gel electrophoresis［J］. J Cancer Res Clin Oncol, 2010, 136(10): 1545-1556. ［10］ Krawczyk N, MeierStiegen F, Banys M, et al. Expression of stem cell and epithelialmesenchymal transition markers in circulating tumor cells of breast cancer patients［J］. Biomed Res Int, 2014: 415721. ［11］ Bartkowiak K, Effenberger KE, Harder S, et al. Discovery of a novel unfolded protein response phenotype of cancerstem/progenitorcells from the bonemarrow of breastcancer patients［J］. J Proteome Res, 2010, 9(6): 3158-3168. ［12］ Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early averagetohigh risk breast cancer patients［J］. J Natl Cancer Inst, 2014, In press. ［13］ Woodward WA, Krishnamurthy S, Lodhi A, et al. Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with thepresence of circulating or disseminated tumors cells［J］. J Cancer, 2014, 5(5): 360-367. ［14］ Hill JJ, Tremblay TL, Pen A, et al. Identification of vascularbreast tumormarkers by lasercapture microdissection and labelfree LCMS［J］. J Proteome Res, 2011, 10(5): 2479-2493. ［15］ Semenza GL. Cancerstromal cell interactions mediated by hypoxiainducible factors promote angiogenesis, lymphangiogenesis, and metastasis［J］. Oncogene, 2013, 32(35): 4057-4063. ［16］ Onishi T, Hayashi N, Theriault RL, et al. Future directions of bonetargeted therapy for metastatic breast cancer［J］. Nat Rev Clin Oncol, 2010, 7(11): 641-651. ［17］ Ma H, Liang C, Wang G, et al. MicroRNAmediated cancer metastasis regulation via heterotypic signals in the microenvironment［J］. Curr Pharm Biotechnol, 2014, 15(5): 455-458. ［18］ Hong B, Li H, Zhang M, et al. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion［J］. Int J Cancer, 2015, 136(1): 34-43. ［19］ Naba A, Clauser KR, Lamar JM, et al. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters［J］. Elife, 2014, 3: e01308. ［20］ Cawthorn TR, Moreno JC, Dharsee M, et al. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival［J］. PLoS One, 2012, 7(2): e30992. ［21］ Jin L, Zhang Y, Li H, et al. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis［J］. Cell Res, 2012, 22(9): 1356-1373. ［22］ Louie E, Chen XF, Coomes A, et al. Neurotrophin3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis［J］. Oncogene, 2013, 32(35): 4064-4077.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英.免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[12]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[13]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.

Metastatic mechanisms of breast cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价